RMD Open

Anifrolumab, a potential treatment for ADA2 deficiency

Adenosine deaminase 2 deficiency (DADA2) is an inborn error of immunity leading to systemic vasculitis, haematological manifestations, immune deficiency and/or autoimmunity. We report the case of a 26 ...
RMD Open

Dance as a double-edged sword: physiological adaptations, injury risks and therapeutic potential

Dance is a complex physical activity with high biomechanical and artistic demands that cause repetitive stress on the ...
RMD Open

Development and assessment of an assisted diagnosis model using machine learning for identifying adult-onset Still’s disease in fever of unknown origin: a retrospective …

Background Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder lacking a gold-standard diagnostic ...
RMD Open

Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health ins…

Objective Recent advances in giant cell arteritis (GCA) management aim to reduce glucocorticoid (GC). We described changes in ...
RMD Open

Rare variants in genes related to inborn errors of immunity in patients with rheumatoid arthritis and secondary immunodeficiency

Objectives Treatment of rheumatoid arthritis (RA) relies on immunomodulatory drugs that can compromise immunity, inducing secondary immunodeficiency (SID). However, features of SID, such as ...
RMD Open

Prevalence of sarcopenia in patients with rheumatoid arthritis: a cross-sectional study

Objective Sarcopenia, defined by reductions in muscle mass and strength, increases the risk of adverse outcomes in patients with rheumatoid arthritis (RA)—driven in part by chronic inflammation—and is ...
rmdopen.bmj

Current Issue

Short report: Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials (3 July, 2026) ...
rmdopen.bmj

National burden of rheumatoid arthritis in Canada, 1990–2019: findings from the Global Burden of Disease Study 2019 – a GBD collaborator-led study

Objective The objectives of this study were: (1) to describe burden of rheumatoid arthritis (RA) and trends from 1990 to 2019 using the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) ...
rmdopen.bmj

Rheumatoid factor and anticitrullinated protein antibody status jointly influence the association between disease activity and cardiovascular risk in rheumatoid arthritis

Objectives Rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA) are linked to disease activity, severity and cardiovascular risk in rheumatoid arthritis (RA). Since RA-related ...
rmdopen.bmj

Altered dynamic functional network connectivity in rheumatoid arthritis associated with peripheral inflammation and neuropsychiatric disorders

Objective This study explored the dynamic functional connective (DFC) alterations in patients with rheumatoid arthritis (RA) and investigated the correlation between the neuropsychiatric symptoms, ...
rmdopen.bmj

Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study

Objective This report from the NORD-STAR (Nordic Rheumatic Diseases Strategy Trials and Registries) trial aimed to determine if obesity is associated with response to conventional and biological ...
rmdopen.bmj

Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials

Objective To evaluate Definition Of Remission In SLE (DORIS) and Lupus Low Disease Activity State (LLDAS) attainment with belimumab versus placebo in a dataset of pooled phase III clinical trials in ...